Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating [Yahoo! Finance]
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Yahoo! Finance
On January 5, Craig-Hallum upgraded Ironwood to Buy from Hold and increased the price target to $5.70 from $3.80. On the same day, Citizens analyst Jason Butler upgraded Ironwood Pharmaceuticals from Market Perform to Outperform with an $8 price target. This sentiment was posted as the firm cited restored confidence in the core strength of Linzess. Butler noted that the drug's performance eases concerns regarding the company's debt obligations and allows for a renewed focus on the long-term value of its pipeline asset, apraglutide. Butler estimates that Linzess could generate approximately $1.5 billion in brand profit for Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) before its loss of exclusivity. According to the firm's research note, the cash flow from this asset is expected to be more than sufficient to meet the company's existing debt requirements. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is a biotechnology company that develops and commercializes therapies for gastrointes
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceBusiness Wire
- Ironwood Pharmaceuticals (IRWD) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.MarketBeat
IRWD
Earnings
- 2/25/26 - Miss
IRWD
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/19/26 - Form SCHEDULE
- 3/17/26 - Form 4
- IRWD's page on the SEC website